| |
|
| Contact |
Ursula Bardon
Corporate Communications
Boehringer Ingelheim GmbH
55216 Ingelheim / Germany
Phone: +49-6132-77 2622
Fax: +49-6132-72 2622
press@boehringer-ingelheim.com |
|
| Please be advised: Linagliptin is an investigational compound and not approved for clinical use. Please be aware that there may be national differences between countries regarding specific medical information, including licenced uses. Please take into account the information here is designed to supply you with current news in pharmaceutical and medical research and not to promote clinical use of the substances mentioned on this site. |
 |
Prof. Anthony Barnett, UK |
|
 |
Dr. Steven E. Kahn, U.S.A. |
|
 |
Prof. Michael Nauck, Germany |
|
 |
| Terms of use Imprint |
